ObjectiveTo introduce the basic principles of commonly used assessment methods for liver function reserve, and compare the advantages and disadvantages of various assessment methods, so as to provide a reference for hepatectomy of patients with hepatocellular carcinoma (HCC). MethodThe literature on evaluation methods of liver reserve function in patients with HCC at home and abroad in recent years was searched and summarized. ResultsFrom the results of literature review, the Child‐Pugh score and indocyanine green discharge test were the most commonly used to assess preoperative liver function reserve for patients with HCC. The application value of other examinations such as albumin-bilirubin score, gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI), nuclear medical imaging in predicting post-hepatectomy liver failure was gradually being explored. ConclusionsThe combination of clinical parameters and volumetric studies is used to assess preoperative liver function reserve for patients with HCC. The clinical applications of nuclear medical imaging and Gd-EOB-DTPA-enhanced MRI make up for the deficiency of local liver function reserve evaluation, which are important examinations to assess liver function reserve after conversion therapy in the future. However, more domestic studies are still needed to confirm their values.
Objective To investigate the risk factors for hypotension in liver failure patients during double plasma molecular adsorption system (DPMAS) treatment, providing a theoretical basis for targeted clinical prevention and intervention. Methods Liver failure patients undergoing DPMAS at West China Hospital of Sichuan University between March 2021 and March 2023 were retrospectively enrolled. General data and clinical indicators were compared between the hypotension group and non-hypotension group. Multivariate logistic regression analysis was used to identify risk factors for hypotension. Results Of the 403 included patients, 60 (14.89%) developed hypotension, while 343 (85.11%) did not. Univariate analyses showed statistically significant differences between groups in age, sex, body mass index (BMI), albumin, serum sodium, pre-treatment systolic blood pressure, pre-treatment diastolic blood pressure, pre-treatment mean arterial pressure, and intraoperative vasoactive drug use (P<0.05). Multivariate logistic regression revealed that low BMI [odds ratio (OR)=0.712, 95% confidence interval (CI) (0.587, 0.863)], low serum sodium [OR=0.715, 95%CI (0.646, 0.792)], and intraoperative vasoactive drug use [OR=11.382, 95%CI (4.438, 29.194)] were independent risk factors for hypotension (P<0.05). Receiver operating characteristic curve analysis combining these three factors yielded an area under the curve of 0.922 [95%CI (0.886, 0.957)] for predicting hypotension incidence. Conclusions Low serum sodium, intraoperative vasoactive drug use, and low BMI are significant risk factors for hypotension during DPMAS therapy. Clinical emphasis should be placed on anticipating and mitigating hypotension to ensure uninterrupted treatment, reduce economic burdens, and improve patient prognosis.
ObjectiveTo systematically evaluate the risk factors for posthepatectomy liver failure (PHLF) of hepatobiliary malignancies in order to provide evidence-based medical basis for preventing and reducing PHLF.MethodsThe case-control studies on the risk factors of PHLF for hepatobiliary malignancy were searched in PubMed, CNKI, etc. domestic and foreign databases from January 2011 to March 2020. The quality evaluation of the literatures was performed by using the Newcastle-Ottawa Scale. Meta-analysis was performed using RevMan 5.3.ResultsA total of 43 studies were included, involving 13 075 patients after hepatectomy, of which 1 943 (14.86%) had PHLF. Meta-analysis results showed that the male, liver cirrhosis, portal hypertension, hepatectomy range ≥3 segments, vascular tumor thrombus, intraoperative blood transfusion, tumor number ≥2, Child-Pugh grade ≥B, less platelet count, lower albumin, higher total bilirubin, higer indocyanine green retention rate at 15 minutes, longer hepatic hilar occlusion time, longer operation time, more intraoperative blood loss, bigger maximum tumor diameter, smaller residual liver volume, and higer MELD score were the risk factors for the occurrence of PHLF (P<0.05).ConclusionsAccording to the risk factors of PHLF, the basic condition, liver function, and residual liver volume should be fully evaluated before operation. The operation should be accurate anatomy, adequate hemostasis, timely treatment of intraoperative complications. After operation, the fluid infusion, anti-infection, correction of coagulation dysfunction, and protection of liver function should be strengthened. So incidence of PHLF might be reduced minimally.
The main treatment strategies for hepatic failure include drug therapy, artificial liver support system, and liver transplantation. This article introduces the clinically commonly used non biological artificial liver techniques, including plasma exchange, continuous blood purification, plasma bilirubin adsorption, plasma diafiltration, repeatedly pass albumin dialysis, molecular adsorbent recirculating system, Prometheus system, etc; and discusses how to select different artificial liver techniques according to different clinical manifestation. At the same time, the progress of bioartificial liver in recent years is summarized, and the future development of artificial liver is prospected.
ObjectiveTo identify the risk factors for liver failure in patients with recurrent liver cancer after hepatectomy who underwent transcatheter arterial chemoembolization (TACE) therapy, and to develop a nomogram predictive model. MethodsThe patients who underwent TACE therapy for recurrent liver cancer after hepatectomy at Haian People’s Hospital Affiliated to Nantong University from December 2018 to January 2023 were retrospectively enrolled. The patients were randomly divided into a training set and a validation set in a 7∶3 ratio. The risk factors for liver failure after TACE therapy were identified using univariate and multivariate logistic regression analyses in the training set. A nomogram predictive model was then developed incorporating the identified risk factors. The discriminative ability of the nomogram predictive model was evaluated using the area under the receiver operating characteristic curve (AUC). The calibration curve and decision curve analysis (DCA) were applied to assess calibration performance and clinical utility, respectively. ResultsA total of 458 patients were included (321 in the training set, 137 in the validation set), among them, 108 (23.58%) developed liver failure. The multivariate analysis revealed seven independent predictors associated with an increased risk of liver failure (all P<0.05): diabetes mellitus, liver cirrhosis, preoperative Child-Pugh grade C, intraoperative blood transfusion and prolonged hepatic inflow occlusion, postoperative remnant liver volume <40%, as well as elevated total bilirubin (TBIL) level prior to TACE therapy. The nomogram constructed based on these factors achieved AUCs (95%CI) of 0.887 (0.843, 0.921) in the training set and 0.820 (0.735, 0.880) in the validation set. The calibration curves approximated the ideal line, and the Hosmer-Lemeshow test indicated good agreement between predictions and observations (training set: χ2=8.849, P=0.355; validation set: χ2=8.362, P=0.399). DCA demonstrated a high net clinical benefit within threshold probability ranges of 0.02–0.93 for the training set and 0.02–0.83 for the validation set. ConclusionsThe findings of this study indicate that heightened vigilance is required regarding the risk of liver failure in patients with high-risk factors following TACE therapy for liver cancer. These factors include comorbidities such as diabetes mellitus and liver cirrhosis, preoperative Child-Pugh grade C, intraoperative blood transfusion during hepatectomy and prolonged duration of hepatic inflow occlusion, postoperative small remnant liver volume, or elevated TBIL level prior to TACE therapy. The nomogram predictive model constructed based on these risk factors demonstrates favorable performance in the early prediction of liver failure risk after TACE therapy.
ObjectiveTo summarize the changes and mechanism of related genes induced by stem cell therapy in acute-on-chronic liver failure (ACLF) in recent years, and in order to guide the clinical value of ACLF and curative effect evaluation.
MethodsThrough searching Wanfang med, CNKI, Pubmed database and so on in recent years, the differentially expressed genes induced by stem cell therapy for ACLF in recent years was retrieved and the changes of related genes induced during the treatment process were discussed.
ResultsBoth at home and abroad had reported that stem cell therapy in the process of ACLF caused mir-27b, TRAIL, and Tg737 genetic changes, some genetic changes had an fixed change trend.
ConclusionsStem cells in the treatment of ACLF, cause mir-27b, TRAIL, Tg737 genetic changes, which can provides a new way and method for monitoring stem cell therapy ACLF.
Objective To explore the safety and efficacy of plasma diafiltration (PDF) in the treatment of liver failure. Methods Patients with liver failure requiring artificial liver treatment in West China Hospital of Sichuan University from December 2020 to December 2022 were selected and divided into three groups according to treatment modality: PDF group, double plasma molecular adsorption system (DPMAS) group and plasma exchange (PE) group. Serum albumin levels and total bilirubin (TB) levels were tested before and after treatments to compare the clearance of these substances among three groups. Adverse events were recorded. Results A total of 88 patients were included, with a total of 179 treatments conducted. Among them, 27 cases in PDF group were treated for 62 times. In PE group, 18 cases were treated for 33 times. In DPMAS group, 43 cases were treated for 84 times. There were no significant differences between the three groups in age, sex, TB, international standardized ratio, albumin, hemoglobin, blood pH value, blood sodium, blood potassium, blood free calcium, or lactate (P>0.05). There was no statistically significant difference in the absolute value of TB decrease, percentage of TB decrease, absolute value of albumin change, and percentage of albumin change before and after treatment among the three groups (P>0.05). Transient hypotension occurred in one patient in DPMAS group. There were two and three allergic reactions in PDF and PE groups, respectively. In addition, 2 patients in PE group had hypocalcemia. Conclusions PDF can be safely used in patients with liver failure, and its therapeutic effect on reducing bilirubin is similar to DPMAS and PE groups. Compared with PE, it needs less plasma supplement. As it can provide ultrafiltration, PDF would be helpful in patients with liver failure accompanied by renal insufficiency oliguria.
